Treatment News : ViiV Submits Single-Pill Combo of Tivicay and Epzicom to FDA

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 18, 2013

ViiV Submits Single-Pill Combo of Tivicay and Epzicom to FDA

ViiV Healthcare has submitted an application to the U.S. Food & Drug Administration for approval of a single-tablet antiretroviral (ARV) regimen to treat HIV that combines Tivicay (dolutegravir) and Epzicom (abacavir/lamivudine). If approved, the drug, which is sometimes referred to as “Trii,” would join Atripla, Stribild and Complera in the highly competitive field of single-tablet regimen players. The submission comes on the heels of Tivicay’s August 2013 FDA approval for use in combination with other ARVs.

“People living with HIV and their doctors seek to use appropriate treatment options for the individual, while also trying to minimize the number of pills required for effective and acceptable antiretroviral treatment,” John Pottage, MD, chief medical officer of ViiV Healthcare, said in a release. “This submission aims to make a complete Tivicay-based regimen available for the first time in a single once-daily pill.”

In the near future, ViiV also plans to submit an application in Europe to the Marketing Authorisation Application.

ViiV’s American submission is based on data from one Phase III study and is supported by three other Phase III/IIIb studies that evaluated the safety and efficacy of the drug regimen. The submission also includes data comparing the equivalence between the single- and the double-tablet regimen in how the body processes the three drugs. There is also an ongoing Phase IIIb/IV study of the single-tablet regimen among treatment-naive women with HIV.

To read the ViiV announcement, click here.

Search: ViiV Healthcare, Tivicay, dolutegravir, Epzicom, abacavir, lamivudine, Atripla, Stribild, Complera, U.S. Food & Drug Administration, Marketing Authorisation Application, John Pottage.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.